Ketorolac eyedrops and ranibizumab combo reduces CMT

Article

A combination of ketorolac eyedrops 0.45% and intravitreal ranibizumab reduces central macular thickness (CMT) in choroidal neovascularisation (CNV), reveals a recent paper.

A combination of ketorolac eyedrops 0.45% and intravitreal ranibizumab reduces central macular thickness (CMT) in choroidal neovascularisation (CNV), reveals a recent paper.

Dr Andrea Russo et al., Department of Neurological and Vision Sciences, Eye Clinic, University of Brescia, Italy, conducted a pilot study on 56 patients who were randomized to receive the combination treatment (group 1) or ranibizumab alone (group 2).

All patients were administered monthly 0.5 mg ranibizumab injections for 3 months and in accordance with standard of care thereafter. Group 1 patients self-administered one drop of ketorolac three times a fay for six months and all patients underwent six months follow-up.

At the six-month follow-up both groups demonstrated a significant improvement in best-corrected visual acuity. The mean six-month change in CMT was −124 µm and −86.9 µm in groups 1 and 2, respectively. The combo group’s change in CMT was greater than the ranibizumab-only group. The combo treatment presented no adverse effects.

The combo treatment was found to be safe effective for reducing CMT. Topical ketorolac could actually supplement the activity of intravitreal ranibizumab in reducing CMT in CNV.

The abstract can be viewed in the British Journal of Ophthalmology.

Related Videos
A screenshot of Dr Filomena Ribeiro, president of the ESCRS
Ramin Tadayoni, MD, speaks with Sheryl Stevenson
Jennifer I. Lim, MD, FARVO, FASRS, Director of Retina Service, University of Illinois at Chicago
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center
Carl D. Regillo, MD, FACS, FASRS, Chief of Retina Service, Wills Eye Hospital, Philadelphia, PA
Arshad Khanani, MD, MA FASRS, on a virtual call
Diana Do, MD, Professor of Ophthalmology, Byers Eye Institute, Stanford University, discusses the PHOTON study results as presented AAO
© 2024 MJH Life Sciences

All rights reserved.